Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, budesonide (Jorveza®) cannot be endorsed for use within NHS Wales as maintenance therapy for eosinophilic esophagitis in adults (older than 18 years of age). |
||
|
||
Medicine details |
||
| Medicine name | budesonide (Jorveza®) | |
| Formulation | 0.5 mg and 1 mg orodispersible tablet | |
| Reference number | 4507 | |
| Indication | As maintenance therapy for eosinophilic esophagitis in adults (older than 18 years of age) |
|
| Company | Dr Falk Pharma UK Ltd | |
| BNF chapter | Gastro-intestinal system | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 24/09/2020 | |